Welkom op Campus Sanofi

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives⁸.

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.¹ The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.² Assays for detecting autoimmune T1D have shown high sensitivity and specificity.^3,4

Klinische casus: Een 18-jarige met heuppijn en mank lopen

In this episode of Polyp Gossip, we dive into the real-life experiences of patients living with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), exploring how the condition impacts their daily routines, relationships, and overall well-being. Our guests share their journeys, shedding light on the emotional and physical toll of the condition.

Polyp Gossip is a video podcast dedicated to exploring Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Hosted by two globally recognized rhinologists. The show delves into trending topics, latest advancements, and patient experiences. Each episode features esteemed guests, including experts and patients, offering valuable insights into the evolving world of CRSwNP.

Evaluating the effect of dupilumab on type 2 airway inflammation and mucus plugging in patients with uncontrolled moderate-to-severe asthma.¹